-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WoEQCE0lTQ8zhmgf99cfiF35Urab95cA1t3/RlM1PcY9/kClg9PeE7htZDut/2ds
 fsozInLgmlHShZJKNHiakg==

<SEC-DOCUMENT>0000922423-05-001098.txt : 20050708
<SEC-HEADER>0000922423-05-001098.hdr.sgml : 20050708
<ACCEPTANCE-DATETIME>20050708113258
ACCESSION NUMBER:		0000922423-05-001098
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20050708
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20050708
DATE AS OF CHANGE:		20050708

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEPHROS INC
		CENTRAL INDEX KEY:			0001196298
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133971809
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32288
		FILM NUMBER:		05944988

	BUSINESS ADDRESS:	
		STREET 1:		3960 BROADWAY
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10032
		BUSINESS PHONE:		2127815113
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>kl00713_8-k.txt
<DESCRIPTION>FORM 8-K CURRENT REPORT
<TEXT>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                           __________________________


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


          Date of report (Date of earliest event reported) July 8, 2005
                                                           ------------

                                  Nephros, Inc.
               (Exact Name of Registrant as Specified in Charter)

                        Commission File Number: 001-32288
                                                ---------


           Delaware                                         13-3971809
           --------                                         ----------
 (State or other Jurisdiction                            (I.R.S. Employer
              of                                       Identification No.)
        Incorporation)

                     3960 Broadway, New York, New York 10032
                     ---------------------------------------
                    (Address of Principal Executive Offices)
                                   (Zip Code)


                                 (212) 781-5113
                                 --------------
              (Registrant's telephone number, including area code)

                                 Not Applicable
                                 --------------
          (Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))


<PAGE>

Item 8.01. Other Events.

      On July 8, 2005, Nephros, Inc. issued a press release announcing that it
has received confirmation from the United States Patent and Trademark Office
that it will be receiving a patent on its OLpur(TM) H2H(TM) product. The full
text of this press release is attached hereto as Exhibit 99.1. The information
in this report shall not be deemed to be "filed" for the purposes of Section 18
of the Securities Exchange Act of 1934 or otherwise subject to the liability of
that Section.

Item 9.01.  Financial Statements and Exhibits.

      (c)   Exhibits

      99.1  Press Release issued by Nephros, Inc. dated July 8, 2005.










<PAGE>


                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Date: July 8, 2005



                                    NEPHROS, INC.

                                    By: /s/ Marc L. Panoff
                                        ---------------------------------
                                        Marc L. Panoff
                                        Chief Financial Officer (Principal
                                        Financial and Accounting Officer)




</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>kl00713_99-1.txt
<DESCRIPTION>EXHIBIT 99.1 PRESS RELEASE
<TEXT>

                                                          FOR IMMEDIATE RELEASE


Contacts:
Marc Panoff, CFO              Garth Russell / Todd Fromer
Nephros, Inc.                 KCSA Worldwide
Tel: 212-781-5113             212-896-1250 / 212-896-1215


           NEPHROS, INC. TO RECEIVE U.S. PATENT FOR OLpur(TM) H2H(TM)
                                       ---

NEW YORK, July 8, 2005 -- Nephros, Inc. (AMEX: NEP) announced today it has
received confirmation from the United States Patent and Trademark Office that it
will be receiving a patent on its OLpur(TM) H2H(TM) product, which incorporates
proprietary technologies that allow users of conventional hemodialysis machines
to perform convective-based hemodiafiltration (HDF) therapies with on-line
ultra-pure substitution fluid. Nephros believes that its OLpur(TM) H2H(TM)
product will permit it to introduce on-line HDF therapy to the U.S. dialysis
market without the need for clinics to replace their existing hemodialysis
machines. The OLpur(TM) H2H(TM) has been designed to operate with the most
common hemodialysis machines. The FDA has not yet approved HDF with on-line
substitution fluid or use of the OLpur(TM) H2H(TM) or OLpur(TM) MD190 products.

The application from which the patent will issue is serial No. 10/072,464,
entitled "Method and Apparatus for a Hemodiafiltration Delivery Module."

Nephros believes its H2H(TM) technology can significantly reduce the cost of
providing HDF compared to traditional methods of using terminally sterilized
fluids for these applications. "Hemodiafiltration with on-line substitution
fluid is not currently available in the U.S.; this patent allowance gives us the
exclusive right to use the OLpur(TM) H2H(TM) product to open up the U.S. market
to HDF. Together with our premier OLpur(TM) MD190 mid-dilution hemodiafilter, we
believe we will be in a position to provide the best therapy available to the
more than 1,000,000 patients with end-stage renal disease worldwide. We believe
our product line will offer patients a unique combination to gain potentially
substantial therapeutic benefits, while clinics can use their current dialysis
equipment in order to achieve these marked benefits with potentially sizeable
associated savings," said Norman Barta, Nephros CEO.

About Nephros, Inc.
Nephros, Inc., headquartered in New York, is a medical device company developing
and marketing products designed to improve the quality of life for the end-stage
renal disease (ESRD) patient, while addressing the critical financial and
clinical needs of the care provider. ESRD is a disease state characterized by
the irreversible loss of kidney function. Nephros believes that its products
remove a range of harmful substances more effectively, and more
cost-effectively, than existing treatment methods; particularly with respect to
substances known collectively as "middle molecules," due to their molecular
weight, that have been found to contribute to such conditions as carpal tunnel
syndrome, dialysis related amyloidosis, degenerative bone disease, and
ultimately, to mortality in the ESRD patient.


<PAGE>

Forward-Looking Statements
This news release contains certain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995, as amended.
Such statements may include statements regarding the efficacy and intended use
of Nephros's technologies under development, the timelines for bringing such
products to market and the availability of funding sources for continued
development of such products and other statements that are not historical facts,
including statements which may be preceded by the words "intends," "may,"
"will," "plans," "expects," "anticipates," "projects," "predicts," "estimates,"
"aims," "believes," "hopes," "potential" or similar words. For such statements,
we claim the protection of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements are not guarantees of future performance, are based
on certain assumptions and are subject to various known and unknown risks and
uncertainties, many of which are beyond the control of Nephros. Actual results
may differ materially from the expectations contained in the forward-looking
statements. Factors that may cause such differences include the risks that: (i)
potential products that appeared promising to Nephros in early research or
clinical trials may not demonstrate efficacy or safety in subsequent
pre-clinical or clinical trials; (ii) Nephros may not obtain appropriate or
necessary governmental approvals; (iii) product orders may be cancelled,
patients currently using Nephros's products may cease to do so and patients
expected to begin using Nephros's products may not; (iv) Nephros may not be able
to obtain funding if and when needed; (v) HDF therapy may not be accepted in the
United States and/or Nephros's technology and products may not be accepted in
target markets; (vi) Nephros may not be able to sell its products at competitive
prices or profitably; and (vii) the patent may not enable Nephros to secure or
enforce adequate legal protection for its products. More detailed information
about Nephros and the risk factors that may affect the realization of
forward-looking statements is set forth in Nephros's filings with the Securities
and Exchange Commission, including Nephros's Annual Report on Form 10-KSB filed
with the SEC for the fiscal year ended December 31, 2004 and its Quarterly
Report on Form 10-QSB filed with the SEC for the fiscal quarter ended March 31,
2005. Investors and security holders are urged to read those documents free of
charge on the SEC's web site at www.sec.gov. Nephros does not undertake to
publicly update or revise its forward-looking statements as a result of new
information, future events or otherwise.


                                       # # #

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
